Menu Search
Equities

PsyBio Therapeutics Corp

PSYB:MUN

PsyBio Therapeutics Corp

Actions
  • Price (EUR)0.0015
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-91.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 27 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-3.84m
  • Incorporated2021
  • Employees4.00
  • Location
    PsyBio Therapeutics Corp4400 Sample Road; Suite138COCONUT CREEK 33073United StatesUSA
  • Phone+1 (513) 449-9585
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.